All About Multiple Sclerosis

More MS news articles for June 2004

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

Multiple Sclerosis 15 June 2004, vol. 10, no. Supplement 1, pp. 58-61(4)
Stüve O.[1]; Kita M.[2]; Pelletier D.[1]; Fox R.J.[3]; Stone J.[1]; Goodkin D.E.[4]; Zamvil S.S.[1]
[1] Department of Neurology, University of California, San Francisco, CA, USA [2] Virginia Mason Multiple Sclerosis Center, Seattle, WA, USA [3] Department of Neurology, Mellen Center for MS, Cleveland Clinic Foundation, Cleveland, OH, USA [4] Multiple Sclerosis Therapeutics, Biogen, Cambridge, MA, USA

Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS).

Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.